Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer
Shinako Araki, … , David A. Boothman, Lindsey D. Mayo
Shinako Araki, … , David A. Boothman, Lindsey D. Mayo
Published December 1, 2009
Citation Information: J Clin Invest. 2010;120(1):290-302. https://doi.org/10.1172/JCI39194.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 10

TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer

  • Text
  • PDF
Abstract

The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%–80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells to TGF-β1. Whether TGF-β1 signaling induces Hdm2 expression leading to HDM2-mediated destabilization of p53 has not been investigated. In this study, we report that TGF-β1–activated SMA- and MAD3 (Smad3/4) transcription factors specifically bound to the second promoter region of HDM2, leading to increased HDM2 protein expression and destabilization of p53 in human cancer cell lines. Additionally, TGF-β1 expression led to Smad3 activation and murine double minute 2 (Mdm2) expression in murine mammary epithelial cells during epithelial-to-mesenchymal transition (EMT). Furthermore, histological analyses of human breast cancer samples demonstrated that approximately 65% of late-stage carcinomas were positive for activated Smad3 and HDM2, indicating a strong correlation between TGF-β1–mediated induction of HDM2 and late-stage tumor progression. Identification of Hdm2 as a downstream target of TGF-β1 represents a critical prosurvival mechanism in cancer progression and provides another point for therapeutic intervention in late-stage cancer.

Authors

Shinako Araki, Jacob A. Eitel, Christopher N. Batuello, Khadijeh Bijangi-Vishehsaraei, Xian-Jin Xie, David Danielpour, Karen E. Pollok, David A. Boothman, Lindsey D. Mayo

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Total
Citations: 2 4 5 1 5 2 8 3 5 2 3 10 5 15 7 6 83
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2012 (15)

Title and authors Publication Year
The ubiquitin–proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer
IA Voutsadakis
Journal of Biomedical Science 2012
Ubiquitination and the Ubiquitin–Proteasome System as regulators of transcription and transcription factorsin epithelial mesenchymal transition of cancer
IA Voutsadakis
Tumor Biology 2012
Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity
A Sundqvist, P Dijke, H Dam
Breast Cancer Research 2012
Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect
D Klokov, K Leskov, S Araki, Y Zou, EM Goetz, X Luo, D Willson, DA Boothman
Oncogene 2012
CCN5/WISP-2: A micromanager of breast cancer progression
SK Banerjee, S Banerjee
Journal of Cell Communication and Signaling 2012
Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2
W Wang, X Zhang, JJ Qin, S Voruganti, SA Nag, MH Wang, H Wang, R Zhang
PloS one 2012
Vitamin D directly regulates Mdm2 gene expression in osteoblasts
H Chen, G Reed, J Guardia, S Lakhan, O Couture, E Hays, N Chandar
Biochemical and Biophysical Research Communications 2012
CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms
WB Fang, I Jokar, A Zou, D Lambert, P Dendukuri, N Cheng
The Journal of biological chemistry 2012
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy
Q Li, G Lozano
Clinical cancer research 2012
The Many Faces of MDM2 Binding Partners
MF Riley, G Lozano
Genes & cancer 2012
Transcription factor NFAT1 activates the mdm2 oncogene independent of p53
X Zhang, Z Zhang, J Cheng, M Li, W Wang, W Xu, H Wang, R Zhang
The Journal of biological chemistry 2012
Identification of FDA-approved drugs that computationally bind to MDM2
WA Warner, R Sanchez, A Dawoodian, E Li, J Momand
Chemical Biology & Drug Design 2012
Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function
DP Frazier, RD Kendig, F Kai, D Maglic, T Sugiyama, RL Morgan, EA Fry, SJ Lagedrost, G Sui, K Inoue
Cancer research 2012
MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress
L Biderman, MV Poyurovsky, Y Assia, JL Manley, C Prives
Molecular and cellular biology 2012
Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.
Qin JJ, Nag S, Voruganti S, Wang W, Zhang R
Current medicinal chemistry 2012

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 2
107 readers on Mendeley
See more details